Stock Quote

Global Cannabis Value Expected to Keep Growing as North America Dominates the Market

NEW YORK, October 8, 2018 /PRNewswire/ --

According to data compiled by Genesis Market Insights, the global marijuana market was valued at USD 17.18 Billion in 2017 and is projected to reach USD 58.90 Billion during the forecast period of 2018 to 2023. The main driver for the market is the widespread legalization of recreational and medical cannabis. The medical segment is used to treat conditions ranging from Alzheimer's to chronic pain, while the recreational market has been booming due to the recent surge in CBD-infused products. Currently, the North American region holds the largest market shares for the industry and is also projected to be the fastest growing market. The U.S. and Canada control the majority of the global cannabis market, but unlike Canada, the U.S. has not legalized cannabis nationwide. Other nations are beginning to enter into the market such as European nations who have legalized medical cannabis and the impending countries who are expected to join. Chemesis International Inc. (OTC: CADMF), Level Brands, Inc. (NYSE: LEVB), CannaRoyalty Corp. (OTC: CNNRF), Cannabis Sativa, Inc. (OTC: CBDS), Vitality Biopharma (OTC: CNNRF)

The cannabis market is positioned for strong growth pending further market legalization. Although, only two countries have legalized cannabis nationwide: Canada and Uruguay. The U.S. currently has 9 states and the District of Columbia that have legalized cannabis for both medical and recreational usage, but multiple other states are now in the process of beginning to legalize it. According to Forbes, California, Colorado and Washington State are the biggest players, driving in almost USD 5 Billion last year. "The industry is at about 5 percent of what it will be someday," concurs Tyler Stratford, director of client operations for cannabis consulting firm Canna Advisors. "Even if the path forward isn't straight, we're certainly on a path forward. The tide has changed, and there's no turning it back now."

Chemesis International Inc. (OTC: CADMF) is also listed on the Canadian Securities Exchange under the ticker (CSE: CSI). Earlier last month, the Company announced breaking news that, "it will be entering into the cannabis infused beverages market. Chemesis will leverage licences and assets it has recently acquired to build out production, storage, and a transportation network for its cannabis infused beverages. The cannabis beverages category includes sports drinks, teas, sodas, coffees, shots, water, and other health and wellness beverages.

With cannabis sales projected to triple from approximately $5.4 billion USD in 2015, to $16 billion USD in 2020, according to a market research, Chemesis sees a significant growing opportunity in the beverages market . Entering into the cannabis beverages market is the next logical step for the Company, as its current facilities and licenses allow this to be accomplished in a relatively short period of time. The Company can accomplish this by leveraging its state licenses for production, distribution, and transportation. Chemesis intends to provide white labelling services for companies, as well as introducing beverages for its own brands. Chemesis will be using the recently acquired Desert Zen Fulfillment facility for this expansion and anticipates products to be launched in Q1 2019.

"Entering into the cannabis infused beverage market is an extremely important step for Chemesis," said CEO Edgar Montero. "The cannabis market is expanding into more product categories, and Chemesis is identifying opportunities that will build long term value and consistent revenues. Our existing licenses and facilities will allow us to expand our portfolio of products without the added regulatory delays. The company will continue to ensure it expands and creates a footprint in markets and product spaces that align with our ambitious business plan."

About Chemesis International Inc. - Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California. Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products. Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale."

Level Brands, Inc. (NYSE: LEVB) is an innovative marketing and licensing company that provides bold, unconventional, and socially responsible branding for leading businesses. Level Brands, Inc., through its licensing agreement with Isodiol International, Inc., recently announced the online launch of five new cannabidiol (CBD) products under the kathy ireland® Health & Wellness brand. "It's very exciting to be at the forefront of the CBD industry, as we educate families about the power of CBD without THC," states Kathy Ireland, Chairman Emeritus and Chief Brand Strategist of Level Brands. "We continue to believe that the CBD industry will see enormous growth over the next decade on a global scale. Recently, the Brightfield Group reported that the global market for CBD could top USD 22 Billion in the next four years. If passed, the 2018 Farm Bill which includes the Hemp Farming Act of 2018, will remove hemp as a designated controlled substance thereby legalizing the crop under federal law, which will allow CBD to be legally sold in all 50 states. The passage of the 2018 Farm Bill, which would replace the 2017 Farm Bill which [expired] on September 30, 2018, would be a significant positive development for the industry." Source:

CannaRoyalty Corp. (OTCQX: CNNRF) is a North American cannabis consumer product company currently focused on building a leading distribution business in California, the world's largest regulated cannabis market. CannaRoyalty Corp. recently announced that it has finalized a definitive agreement with Australis Capital Inc. whereby Australis will purchase 2,200,000 common shares in the capital of Wagner Dimas Inc. from Cannroy Delaware Inc,. a wholly-owned subsidiary of CannaRoyalty. The Agreement replaces the letter of intent signed by the parties on September 17th, 2018. "As CannaRoyalty continues to grow and build a solid presence in California as a cannabis brands company and a major third-party distributor, our focus has been concentrated on realizing value from assets that are non-core to our business. This Agreement cements this stated strategy. The approximately 182% return on investment from the sale of our equity stake in Wagner Dimas reinforces our commitment to generate significant returns for shareholders and fund accretive growth in our key markets in North America," commented Marc Lustig, Chairman and Chief Executive Officer of CannaRoyalty.

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. Cannabis Sativa, Inc.'s subsidiary, PrestoDoctor, recently announced that it is providing online medical marijuana recommendations to Pennsylvania residents via its HIPPA compliant trusted online recommendation platform https://Prestodoctor.Com/ , offering residents a convenient online option when it comes to getting their Pennsylvania Medical Marijuana Card. PrestoDoctor makes the process simple and seamless by providing the state required two doctor appointments completely online, allowing patients to speak to licensed compassionate physicians who specialize in Pennsylvania medical marijuana card / patient evaluations. "Easier access to alternative care is the driving mission at Presto Doctor, and has made PrestoDoctor the #1 rated online medical marijuana recommendation platform," said Chief Executive Officer Kyle Powers, "We are committed to serve patients in Pennsylvania with the integrity we have displayed in California, Nevada and New York."

Vitality Biopharma (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Vitality Biopharma, Inc. recently announced the filing of national patent applications in the United States and Canada that describe compounds discovered to be effective in a drug screening model for neural repair. The discoveries included a compound that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. Cannabidiol (CBD), a non-intoxicating cannabinoid independently FDA-approved in pharmaceutical form for the treatment of epilepsy, is also known to relieve pain through modulation of the TRPV1 receptor. As a result, Vitality has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders. "We're excited to pursue this intellectual property in the U.S. and Canada, and to perform additional work characterizing the regenerative potential of these compounds," said Robert Brooke, Chief Executive Officer of Vitality Biopharma. "By targeting fundamental mechanisms of neural repair, we believe the result could be more powerful therapeutics and treatment regimens that benefit patients across a variety of important disease states."

Subscribe Now! Watch us report LIVE  

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Chemesis International Inc. financial news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.